Abirapro is belongs to anti neoplastic drugs which will work by Diminish the androgen production in the body. Androgen is a male hormone which balances the cancer cell in prostate glands.
Normaly this tablet is taken by combination with prednisolone, a steroid which decreases the liability of side effects produced by Abiraterone.
MECHANISM OF ACTION
Androgens are regulates the production of tumors in prostate. Abirapro is an anti androgen drugs, which causes to eradicate the enzyme 17α-hydroxylase C 17, 20-lyase CYP17), it is includes in androgen synthesis. Decrease the serum testosterone level. Diminished the tumor cell occurred.
Time to median plasma concentration of tablet Abirapro takes 12 hours.
Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.
The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.
Terminal half life of tablet Abirapro is 12 ± 5 hours. The drug mainly excreted in 88% feces and 5% in urine.
The usual dose of Abirapro is endorsed as 4 tablets orally once daily The drug Abirapro given with 5mg prednisolone twice daily in empty stomach. Abirapro Tablets administrated on an empty stomach. No food should be consumed for at least 2 hours before and at least 1 hour after the dose of Abirapro Tablets is taken. Abirapro should be swallowed whole with water. Do not crush or chew the tablets.
Abirapro has no specific antitoxin, If overdose occurs stop the drug and provide general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.
Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency Hepatotoxicity Hypertension, Decrease in ka level Adrenocortical insufficiency
Musculo skeletal and Connective tissue disorders
Joint swelling, discomfort, muscle discomfort
Hot flush, hypertension, arrhythmias, chest pain, cardiac failure
Infections and Infestation
Urinary frequency, nocturia
Abirapro interaction with dextromethorphan will increases the Cmax and AUC of dextromethorphan Abirapro interaction with strong CYP3A inhibitors or inducers , use combination with caution because pharmacokinetics is not evaluated.
If patient having any allergy, severe liver problem, or pregnant, Abirapro tablet should be discontinued Do not take other medications, i.e prescription, over-the-counter, vitamins, herbal remedies, etc be sure to inform the doctors before the treatment. Aspirin do not administering and products containing aspirin till doctor particularly allow the drug.
pregnancy category X (leads to fetal death): During treatment if women become pregnant, immediately stop the drug and give counseling to the women. Abirapro tablet is not recommended for women.
Abirapro is not used in women excretion in human milk is unknown and the drug effects in the nursing infant is unknown.
Stored at 15°C-30°C in a dry place.
If patient missed the dose of Abirapro , that missed dose will be skipped and follow the regular dosing schedule.